937796-13-9 Usage
Uses
Used in Pharmaceutical Synthesis:
(2-MORPHOLINOPYRIMIDIN-5-YL)METHANOL is utilized as a key building block in the creation of various pharmaceuticals. Its unique structure allows it to be a fundamental component in the development of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Development:
Similarly, in the agrochemical industry, (2-MORPHOLINOPYRIMIDIN-5-YL)METHANOL serves as an essential component in the synthesis of crop protection agents and other agricultural products. Its incorporation aids in enhancing the effectiveness and selectivity of these chemicals.
Used in Anticancer Drug Development:
(2-MORPHOLINOPYRIMIDIN-5-YL)METHANOL is considered a promising candidate for the development of anticancer drugs. It has demonstrated the potential to inhibit enzymes that play a crucial role in the growth of cancer cells, thereby offering a new avenue for cancer treatment.
Used in Neurological Disorder Treatment:
(2-MORPHOLINOPYRIMIDIN-5-YL)METHANOL has also been studied for its potential in treating neurological disorders. Its specific properties make it a candidate for further research and development in the context of managing or treating such conditions.
Used as a Potential Antiviral Agent:
Furthermore, (2-MORPHOLINOPYRIMIDIN-5-YL)METHANOL has shown promise as a potential antiviral agent. Its ability to interfere with viral processes suggests that it could be developed into a new therapeutic option for combating viral infections.
Check Digit Verification of cas no
The CAS Registry Mumber 937796-13-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,7,7,9 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 937796-13:
(8*9)+(7*3)+(6*7)+(5*7)+(4*9)+(3*6)+(2*1)+(1*3)=229
229 % 10 = 9
So 937796-13-9 is a valid CAS Registry Number.
937796-13-9Relevant academic research and scientific papers
cGAS ANTAGONIST COMPOUNDS
-
Paragraph 0217; 0238; 0239, (2017/11/06)
Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
NOVEL JNK INHIBITORS
-
Page/Page column 140, (2008/12/07)
Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.
